Pharmacological and alimentary alteration of the gastric barrier.

Best practice & research. Clinical gastroenterology (2014-12-03)
Doron Boltin, Yaron Niv

The gastric barrier contains several lines of defence which protect the epithelium from harmful microbes and toxins. Pre-mucosal defence mechanisms include secreted acid (HCl 0.1 mmol/L) and pepsin, which are capable of denaturing tissue. A tightly adherent mucous layer provides the next line of defence, and physically separates any potentially hazardous substance in the lumen from the mucosal surface. Apical secretion of HCO3(-) maintains a non-acidic microenvironment at the mucosal surface. Membrane-bound phospholipids repel soluble toxins, and sulphydryls scavenge reactive oxygen species. However, when noxious agents overwhelm these mechanisms, the epithelium is damaged. Herein, we discuss the pathological and physiological basis for several disease states which are associated with a breakdown in one or more components of the gastric barrier, including: Helicobacter pylori-associated gastritis, atrophic gastritis, stress-related mucosal disease, age-related gastropathy and portal hypertensive gastropathy. The effect of non-steroidal anti-inflammatory drugs and proton pump inhibitors on the gastric mucosa, is explored. Finally, we outline the alterations in mucosal defence caused by alcohol, caffeine, minerals and vitamins.


胃蛋白酶 来源于猪胃粘膜, powder, ≥250 units/mg solid
胃蛋白酶 来源于猪胃粘膜, lyophilized powder, ≥3,200 units/mg protein
胃蛋白酶 来源于猪胃粘膜, lyophilized powder, ≥2,500 units/mg protein (E1%/280)
胃蛋白酶 来源于猪胃粘膜, powder, ≥400 units/mg protein
胃蛋白酶, powder, European Pharmacopoeia (EP) Reference Standard
胃蛋白酶 来源于猪胃粘膜, powder, slightly beige, ≥500 U/mg
胃蛋白酶 来源于猪胃粘膜, powder, slightly beige, 1200-2400 U/mg
胃蛋白酶 来源于猪胃粘膜, Suitable for manufacturing of diagnostic kits and reagents, lyophilized powder, ≥3200 units/mg protein